Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ATAI Life Sciences N.V. - Common Shares
(NQ:
ATAI
)
2.710
+0.520 (+23.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about ATAI Life Sciences N.V. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June
Today 12:51 EDT
Via
Benzinga
Which stocks are experiencing notable movement on Tuesday?
Today 12:30 EDT
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday
Today 10:38 EDT
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Today 10:30 EDT
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data
Today 9:28 EDT
Atai and Beckley report that a single dose of BPL-003 reduced depression symptoms significantly and safely in treatment-resistant patients.
Via
Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session.
Today 8:30 EDT
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via
Chartmill
5 Biotech Stocks with Highly Anticipated Pending Results
June 26, 2025
Via
Stocktwits
Topics
Intellectual Property
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
June 04, 2025
Via
Benzinga
Atai Life Sciences Stock Rockets On Merger Plans With Beckley Psytech; Retail Traders Eye Every Dip
June 02, 2025
The merger focuses on creating a combined company focused on psychedelic mental health therapies.
Via
Stocktwits
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
May 24, 2025
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
Via
Benzinga
Topics
Government
Atai Life Sciences Stock Soars To 3-Month High As Depression Study Yields Promising Results: Retail Bulls Cheer
May 21, 2025
Atai Life Sciences shares surged 11.4% after Beckley Psytech reported encouraging Phase 2a results of its depression treatment
Via
Stocktwits
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
February 14, 2025
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
Via
Stocktwits
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 13, 2025
Via
Benzinga
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
February 13, 2025
Via
Benzinga
Wondering what's happening in today's after-hours session?
February 12, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
November 15, 2024
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Via
Investor's Business Daily
Topics
Government
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
November 13, 2024
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.
Via
Benzinga
Topics
Artificial Intelligence
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
November 13, 2024
Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position.
Via
Benzinga
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
October 07, 2024
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential.
Via
Benzinga
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
October 04, 2024
Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options.
Via
Benzinga
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
September 15, 2024
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.
Via
Talk Markets
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
September 12, 2024
Via
Benzinga
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
September 10, 2024
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...
Via
Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
September 06, 2024
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a...
Via
Talk Markets
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
Via
Benzinga
Topics
Artificial Intelligence
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
August 24, 2024
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past...
Via
Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
August 15, 2024
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...
Via
Talk Markets
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
August 14, 2024
Atai Life Sciences reports positive early data for its DMT-based depression treatment, VLS-01, and plans a Phase II trial targeting treatment-resistant patients.
Via
Benzinga
ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024
August 13, 2024
ATAI stock results show that ATAI Life Sciences missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
July 31, 2024
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.